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Implications Statement: Women experience pain, mostly mild to moderate, with overnight cervical 46 dilator placement at 15-23 5/7 weeks gestation. About 2/3 of women will use a limited quantity of 47 narcotics if provided. Gabapentin does not decrease the pain with or following dilator placement and does 48 not decrease narcotic use. 49
Introduction 50
Osmotic dilators are commonly used for cervical preparation prior to dilation and evacuation 51 (D&E) procedures. Cervical anesthesia reduces pain with dilator placement [1] ; however, most research 52 to date has focused on dilators and ease of D&E completion, evaluating pain as a secondary outcome [2-53 5]. Insertion of dilators can be more painful than pharmacological cervical preparation, and accounts of 54 how this pain changes over time vary [3, 4, 6] . One trial evaluating use of intrauterine lidocaine for pain 55 relief during laminaria placement asked participants 30 minutes before D&E to self-report their maximum 56 pain level using a visual analog scale (VAS) since dilator insertion; mean pain scores for the post-57 laminaria interval were higher than those recorded at laminaria insertion (44 vs 32 p=.04) [2] . Women's 58 experience with pain during the time between dilator insertion and D&E remains an under-evaluated 59 aspect of their abortion experience. 60
Multimodal pain management is an area of interest across many procedural fields. Providers vary 61 in their strategies for pain management after dilator insertion and may recommend over-the-counter 62 analgesics alone or prescribe oral narcotics. Given the potential for narcotic addiction, studies have been 63 investigating non-narcotic analgesic adjuncts such as gabapentin for various obstetric and gynecologic 64 procedures. Gabapentin is an attractive medication because it is low-cost, non-addictive, and has few 65 medical contraindications for use [7] . Studies regarding preoperative use of gabapentin in abdominal 66 hysterectomy have demonstrated decreased post-operative narcotic use, decreased nausea and vomiting, 67 and increased patient satisfaction [8] [9] [10] [11] [12] [13] . A systematic review demonstrated a significant benefit of pre-68 operative gabapentin for preemptive analgesia for abdominal hysterectomy [14] . Data regarding 69 preoperative gabapentin use in other contexts, such as Cesarean delivery and laparoscopic ovarian 70 cystectomy, are less consistent [15] [16] [17] [18] [19] [20] . The heterogeneity of gabapentin dosing and overall pain regimen 71 along with study design limitations make these data challenging to generalize to abortion procedures. The 72 goal of this study is to evaluate the effect of gabapentin on pain experienced after osmotic dilator 73 placement prior to D&E. 74 5
Materials and methods 75
We conducted this randomized, double-blind, placebo-controlled trial at the University of 76 California, Davis Medical Center. We enrolled women 15 weeks 0 days to 23 weeks 5 days gestation on 77 the day prior to a planned D&E procedure for whom the surgical plan included osmotic dilator placement 78 for overnight cervical preparation. We included women 18 years or older, English-speaking, with an 79 active cell phone with text messaging capabilities, and a ride home from clinic. We excluded women 80 currently taking gabapentin, with an allergy to gabapentin or our standard clinic analgesics (ibuprofen or 81 acetaminophen with codeine), with active renal disease, or currently using narcotics. The UC Davis 82
Institutional Review Board approved this study and all study subjects gave written consent prior to 83
enrollment. 84
After obtaining baseline demographic information, we randomized subjects 1:1, with 85 stratification based on vaginal parity, to receive two doses of gabapentin 600 mg or placebo. Subjects 86 took the first study drug dose after randomization and instructed to take the second dose 8 hours after 87 dilator placement. The UC Davis Investigational Drug Service (IDS) over-encapsulated the study drug 88 and placebo tablets to create identical-appearing medication. The IDS performed the randomization 89 allocation using a computer-generated random sequence in blocks of four for two groups (vaginally 90 nulliparous and vaginally parous), prepared sequentially numbered vials for each group with appropriate 91 treatment, and maintained the randomization log to ensure drug allocation concealment until study 92 completion. 93
Family Planning fellows or Obstetrics and Gynecology residents under the supervision of Family 94
Planning faculty aimed to place osmotic dilators 30-60 minutes after intake of the first study drug dose. 95
All physicians followed a standardized clinic protocol for dilator placement (online Appendix Figure 1 ) 96 using 4 mm Dilapan-S® and cervical anesthesia with lidocaine 1% 20 mL. We used adjunctive 97 mifepristone for gestations 22 or more weeks or if the physician placed fewer than the preferred number 98 of dilators. Subjects in this study did not receive misoprostol. We gave each subject prescriptions for 20 99 tablets each of ibuprofen 800 mg (1 tablet every 8 hours as needed) and acetaminophen with codeine 100 6 300/30 mg (1-2 tablets orally every 4-6 hours as needed) with instructions to use these medications as 101 needed for pain management after dilator insertion. 102
We evaluated pain using an 11-point numeric rating scale score (NRS; scale 0-10) and assessed 103 gabapentin-specific side effects of tiredness and dizziness. We asked each subject to verbally provide a 104 baseline NRS score and side effect responses at the time of study drug intake and then at 5 minutes after 105 dilator placement. Each subject received text messages at 2, 4, and 8 hours after dilator placement to 106 ascertain current NRS scores for pain, perceived tiredness or dizziness, and the quantity of interval 107 analgesic use (ibuprofen and acetaminophen with codeine). The 8-hour text included a prompt to take the 108 second dose of study drug. Upon presentation for D&E procedure the subsequent day (approximately 18-109 24 hours after dilator placement), we asked the subject to verbally provide a NRS pain score, current 110 tiredness or dizziness, and analgesic use since the 8-hour text message. 111
The primary outcome was median change in NRS score from baseline to 8 hours post dilator 112 insertion. We assessed median change in individual pain score from baseline, as opposed to median group 113 scores at each time point, because using median change in individual pain score has been adopted in other 114 fields as the preferred standard for evaluating pain management [20] . Secondary outcomes included pain 115 score change at other time points, difference in pain scores by gestational age, study drug side effects, and 116 analgesic use. Additionally, we assessed median group pain scores at all post-dilator placement time 117 points to describe women's pain experience with overnight dilator placement. Because narcotic pain 118 medications can impact both pain and side effects, we also performed an analysis of these outcomes in 119 women who did not use narcotics. 120
We estimated a sample size based on a prior study that utilized an 11-point NRS to assess 121 immediate post dilator pain as a secondary outcome, reporting a mean score of 5.2 ± 1.2 [4]. We 122 calculated 12 women per group would demonstrate a clinically meaningful pain difference of 2-points on 123 NRS with 80% power and α=0.05 [21] . We doubled the sample to allow for stratification by vaginal 124 parity, and then doubled the size again to 48 per group to allow for adequate evaluation of the primary 7 and secondary outcomes. We increased the sample by 20% to account for incomplete follow-up or other 126 limitations, yielding a final sample of approximately 120 women. 127
We performed a modified intention-to-treat analysis, including only women who provided any 128 follow-up NRS information. We compared baseline characteristics among treatment groups using Fisher's 129
Exact Test or Chi-square test as indicated, t-test for continuous variables, and Mann Whitney U for 130 comparing median pain scores. We categorized pain scores post hoc as none, mild (1-3), moderate (4-6), 131 or severe (7-10). We completed analyses using SPSS version 25 (Armonk, NY). 132 133
Results 134
We randomized 121 women from March 2017 to April 2018 and excluded 3 women from the 135 outcome analysis, one due to randomization error, one due to an allergic reaction after dilator placement 136 who had received placebo, and one who did not provide any follow-up NRS data ( Figure 1 ). The 137 characteristics of the 118 women (60 in the gabapentin group and 58 in the placebo group) who 138 completed the study are presented in Table 1 . The mean gestational age for the population was 19 weeks 139 3 days. Physicians completed dilator placement 42.3 ± 11.2 minutes after initial study drug intake in the 140 gabapentin group and 44.2 ± 9.8 minutes in the placebo group (p=0.33). Nine (15%) and 15 (26%) 141 women, respectively, received mifepristone. The final study evaluation occurred 22.8 ± 2.0 hours and 142 22.9 ± 1.8 hours, respectively, after dilator placement (p=0.91). 143
Median change in NRS pain score from baseline is presented in Table 2 . Fifty-eight (97%) 144 women in the gabapentin group and 52 (88%) women in the placebo group provided 8-hour NRS 145 responses, the primary outcome. Median change in pain score from baseline to 8 hours post-dilator 146 placement did not differ (2 vs. 2.5, p=0.52); this absence of effect persisted at all time points after dilator 147 placement (5 minutes, 2 hours, 4 hours, and 18-24 hours). When evaluating median change in NRS scores 148 by parity, we found no statistical differences between gabapentin and placebo users at any time point, 149 though we did observe a clinically significant difference of 2 points at 5 minutes, 4 hours and 8 hours 150 (Table 2) . 151
When evaluating population median values at each time point, we also found no differences in 152 scores at all post-dilator placement time points among treatment groups stratified by vaginal parity except 153 for a 2-point difference at 8 hours in vaginally nulliparous women (online Appendix Figure 2) . 154
Participants provided a very wide range of pain scores at each time point. 155
Women who received gabapentin reported more dizziness or tiredness, both of which reached 156 statistical significance compared to placebo beginning at 2-hours after dilator placement ( Figure 2 Table 3 describes the proportion of women who used pain medication during the time from 161 dilator placement to evaluation in the pre-operative area based on the 118 women who provided responses 162 to analgesic use questions. Most (98 [83%]) women used some analgesia, with 85 (73%) women 163 reporting any ibuprofen use and 75 (64%) reporting any acetaminophen with codeine use. Women who 164 reported higher NRS pain scores more commonly used acetaminophen with codeine than ibuprofen or no 165 pain medication (Table 3) . Acetaminophen with codeine use did not differ between gabapentin 166 (35/60[58%]) and placebo (40/58[69%]) users (p=0.26). Use of ibuprofen or acetaminophen with codeine 167 did not differ by parity, with ibuprofen use by 45 (76%) vaginally nulliparous and 40 (68%) vaginally 168 parous women (p=0.4) and acetaminophen with codeine use by 40 (68%) and 35 (59%), respectively 169 (p=0.4). Few women (n=12, 10%) reported using six or more acetaminophen with codeine tablets, 170 distributed equally among vaginally nulliparous (n=6) and parous (n=6) subjects; the maximum number 171 used was 11. 172
When stratifying by gestational age (≤19 weeks 6 days or ≥ 20 weeks 0 days), we found no 173 difference in maximum reported NRS pain score (median 5 vs 6, p=0.57) or any acetaminophen with 174 codeine use (46/74 [62%] vs. 29/44 [66%], p=0.70). When evaluating pain and side effect outcomes in 175 women who did not use any narcotic (25 gabapentin and 18 placebo subjects), we found no difference in 176 median 8-hour NRS change from baseline (1 vs. 2, p=0.41), maximum reported NRS pain score (median 9 3 vs 3, p=0.96), or side effect profiles between gabapentin and placebo users (data not shown). Sub-178 analysis of the women who received mifepristone showed no difference between gabapentin and placebo 179 users in median 8-hour NRS change from baseline (3 vs. 3, p=0.93), maximum reported NRS pain score 180 (median 7 vs 7, p=0.86) or any acetaminophen with codeine use (5/9 [56%] vs. 10/15 [67%], p=0.68). 181
We describe the overall pain experience of women with overnight dilator placement by reporting 182 median NRS pain scores and severity for the placebo group only in Table 4 . Two of these women 183 In the subset of vaginally nulliparous women, median pain score changes at 5 minutes, 4 hours, 195 and 8 hours from baseline met our a priori designated 2-point clinical difference when comparing 196 gabapentin and placebo groups. Although we recruited a study sample large enough for these differences 197 to be assessed, the outcomes did not achieve statistical significance. We believe the lack of statistical 198 significance is related to the very wide range in responses in both groups, demonstrating the variability in 199 pain experience for each patient. Although gabapentin may provide a benefit for vaginally nulliparous 200 women, we found these women experienced more dizziness and tiredness without a resultant decrease in 201 narcotic use. Thus, the relevant benefit may be negligible. Further research of nulliparous women may 202 identify who may benefit from gabapentin prior to osmotic dilator placement. 203
The lack of a clear benefit with gabapentin use correlates with a recently reported double-blind 204 randomized trial demonstrating that gabapentin did not reduce postoperative pain with first trimester 205 surgical abortion [22] . When considering these findings together with the benefit of pre-emptive 206 gabapentin for pain reduction with abdominal hysterectomy [8] [9] [10] [11] [12] [13] [14] , and the slight and variable pain 207 reduction benefit with cesarean delivery [15-20], perhaps gabapentin is more beneficial for incision-208 related (sensory) pain and less for uterine cramping related (visceral) pain. 209
The medical literature lacks primary data on women's pain experience with dilator placement. 210
Our placebo group provides explicit information about the pain experience with overnight dilators. 211
Nulliparous women generally experience moderate pain after Dilapan-S placement, commonly peaking at 212 2 hours, and may remain the same for at least 6 more hours. Pain for multiparous women appears to peak 213 at 4 hours and decline thereafter. This information will aid providers in patient counseling regarding pain 214 expectations in the hours following osmotic dilator placement. Future studies should more carefully 215 assess the pain course in vaginally nulliparous women more than 8 hours after dilator placement. 216
The broad range of pain scores indicates that some women experience more severe pain. By the 217 time of presentation for D&E the next day, the pain level reported is lower than what is reported at 8 218 hours after dilator placement in parous women but not in nulliparous women, of whom about 20% are 219 still reporting severe pain. We found a correlation of the maximum pain score with acetaminophen with 220 codeine use but not with ibuprofen use, demonstrating that women who experience severe pain will use a 221 narcotic when available, albeit generally fewer than 6 tablets. In our practice we now prescribe fewer 222 narcotic tablets initially and have instituted a mechanism for providing additional analgesics overnight to 223 women who continue to experience pain after finishing their supply. 224
We measured our dilator placement pain score 5 minutes after dilator placement to assess pain 225 free of other factors, including anxiety, that could affect pain at the moment of placement. Prior studies visual analog scale pain score (based on a 10 cm line) of 2.5 cm with gel and 3.9 cm with the paracervical 230 block (p=0.17) with peak pain in both groups during dilator placement. Borgatta et al [4] enrolled women 231 14-16 weeks gestation who received ibuprofen or ketorolac and a cervical anesthetic with lidocaine 1% 232 10 mL prior to placement of 3-6 osmotic dilators (both laminaria and Dilapan, mean 5), resulting in a 233 mean NRS pain score of 5.2 (95% CI 4.0-6.4). Our median NRS pain score 5 minutes after dilator 234 placement of 1-2 is much lower than reported in both studies, likely reflecting how quickly the pain 235 decreases for most women after speculum removal. Of note, the Borgatta et al [4] study did not prescribe 236 oral narcotics to have at home; 2/25 (8%) women made visits to the emergency department overnight to 237 obtain narcotic pain medication. The need for narcotics in this study may reflect the use of more dilators 238 than needed at this gestational age, potentially resulting in more pain [24] . 239
A strength of our study is its large size which allowed ample numbers to evaluate overall 240 outcomes as well as differences related to parity. Additionally, physicians minimized variation by 241 maintaining a standardized osmotic dilator placement protocol across the five family planning 242 subspecialists, two fellows, and residents who provided care to study participants. The study was limited 243 by the enrollment criteria stipulating that participants must have a ride home from the outpatient osmotic 244 dilator placement visit and must have a private cell phone not shared by others; both criteria could 245 disproportionately restrict enrollment of women with limited support or resources. Additionally, the 246 findings may be specific to the dilator regimen used in these participants and may not apply to other 247 osmotic dilator protocols. 248
Though use of adjunctive non-opioid analgesics remains an important focus for abortion care, we 249 showed that gabapentin does not provide benefit for osmotic dilator-associated pain compared to placebo. 250 Women experienced gabapentin side effects but no primary benefit in pain reduction or decrease in 251 narcotic use. We also describe that some women experience significant pain with overnight dilator 252 placement and may utilize a narcotic prescription. The decision to prescribe narcotics should be 253 individualized based on discussions with the patient. The description of the pain women experience 254 following dilator insertion and the associated analgesic use will allow clinicians to provide better 255 counseling and adequately titrate pain medication prescriptions. 
Data presented as n (%) NRS = Numeric rating scale (overall range 0-10) *Includes women who used both acetaminophen with codeine and ibuprofen † Chi-square test; p-value is compared to no use of acetaminophen with codeine ‡ Chi-square test; p-value is compared to use of no pain medication § Chi-square test; p-value is compared to use of any pain medication 
